Loading organizations...
§ Private Profile · 11477 Olde Cabin Road Saint Louis, 63141
Clinical laboratory delivering molecular diagnostics and advanced oncology testing for hospitals, doctors, and pharma.
Key people at Core Diagnostic Corp..
Founded in 2012 by entrepreneurs Zoya Brar and Arghya Basu, CORE Diagnostics operates a premium clinical laboratory specializing in innovative molecular diagnostics and clinical data science. The organization focuses heavily on advanced oncology testing, delivering highly reliable diagnostic services to leading hospitals, independent doctors, and individual patients. Operating with a dedicated workforce of more than 400 employees, the diagnostic provider has successfully processed critical tests for over 500,000 patients while maintaining consistent monthly operational growth. To support this rapid expansion, the enterprise has successfully secured $17 million in total venture funding through investment rounds backed by recognizable institutional investors including Artiman Ventures, F-Prime, and Eight Roads. In addition to its standard clinical services, the growing company collaborates directly with the top 12 pharmaceutical companies to support subsidized oncology testing initiatives across the broader medical industry.
Key people at Core Diagnostic Corp..
Core Diagnostic Corp. is a clinical laboratory specializing in advanced diagnostic solutions primarily for hereditary and sporadic cancers, kidney diseases, and reproductive health. The company leverages cutting-edge molecular biology technologies such as liquid biopsies, digital droplet PCR (ddPCR), real-time PCR (rtPCR), next-generation sequencing (NGS), and Sanger sequencing to provide precise disease stratification and therapy selection. Its services cater to hospitals, research centers, pharmaceutical companies, and individual patients, impacting over 170,000 patient lives and trusted by more than 3,000 doctors. Core Diagnostics generates revenue through partnerships and direct patient services, aiming to enhance diagnostic confidence and reduce retesting by delivering comprehensive biopsy reports and automated cytogenetics and cytopathology platforms[1][2].
Core Diagnostic Corp. is based in Gurgaon, Haryana, India. While specific founding details and key founders are not explicitly documented in the available sources, the company has evolved to become a leading destination for high-end diagnostic testing in India. Its focus on next-generation diagnostics reflects a commitment to bringing advanced testing techniques and expertise to the Indian healthcare market, addressing the need for precise and actionable diagnostic information. Early traction is evident in its rapid growth, with an estimated annual revenue of $211.9 million and a 12% increase in employee count, signaling strong market acceptance and operational expansion[1][2].
Core Diagnostic Corp. rides the global trend toward precision medicine and personalized healthcare, where molecular diagnostics enable tailored treatment strategies. The timing is critical as healthcare systems increasingly demand early, accurate, and actionable diagnostic information to improve patient outcomes and reduce costs. Market forces such as rising cancer incidence, growing awareness of hereditary diseases, and technological advances in genomics and molecular biology favor Core Diagnostics’ growth. By providing advanced diagnostic tools and comprehensive data, the company influences the broader healthcare ecosystem by enabling more informed therapy selection and disease management, thus contributing to the shift from generalized to precision medicine[1][2].
Looking ahead, Core Diagnostic Corp. is well-positioned to expand its footprint in India and potentially international markets by continuing to innovate in molecular diagnostics and integrating emerging technologies like AI-driven data analysis. Trends such as increasing demand for non-invasive liquid biopsies, growth in personalized medicine, and healthcare digitization will shape its trajectory. The company’s influence is likely to grow as it deepens partnerships with pharmaceutical firms and healthcare providers, further embedding its diagnostics into clinical workflows. Continued focus on reducing turnaround times and expanding test portfolios will be key to maintaining competitive advantage and driving future growth[1][2].
Core Diagnostic Corp.’s commitment to precise, actionable diagnostics aligns with the evolving healthcare landscape, making it a pivotal player in advancing patient-centric, technology-driven medical care.